Abbvie

This study is testing a one-time gene therapy injection for wet age-related macular degeneration (wet AMD), a leading cause of vision loss in older adults. The goal is to see if this single treatment can work as well as or better than the current standard of care, which requires …

This is the first human study of an experimental oral drug called ABBV-101 for people with advanced B-cell blood cancers that have returned or not responded to previous treatments. The main goals are to find a safe dose and see how the body processes the drug, while also checking…

This study observes how well the approved medication risankizumab works for people recently diagnosed with moderate plaque psoriasis in real-world Greek clinics. About 250 participants who haven't tried advanced treatments will be followed for two years while taking risankizumab …

This study is testing whether a medication called upadacitinib can help people with Takayasu arteritis stay in remission longer and reduce their need for steroid medications. It involves adults who have recently had a flare-up of this rare autoimmune disease that causes inflammat…

This study is testing whether an investigational drug called lutikizumab can help adults with moderate-to-severe hidradenitis suppurativa, a painful inflammatory skin condition. The research focuses on people who haven't gotten enough benefit from previous anti-TNF treatments, wi…

This study is looking at how well an approved Parkinson's medication called foslevodopa/foscarbidopa works in everyday clinical practice. About 200 French adults with advanced Parkinson's disease will receive the medication via under-skin infusion as prescribed by their doctors. …

This early-stage study is testing a new drug called IMGN151 in patients with recurrent gynecologic cancers that have returned after previous treatments. The main goals are to determine the safest dose, understand how the drug behaves in the body, and see if it shows any early sig…

This study compares two medications, upadacitinib and adalimumab, for adults with moderate to severe rheumatoid arthritis who didn't respond well to a previous TNF inhibitor drug. About 480 participants worldwide will take one of the two drugs along with their current methotrexat…

This study is testing an investigational drug called telisotuzumab vedotin for people with advanced non-small cell lung cancer (NSCLC) that has a specific biomarker called c-Met and has worsened after prior treatments. The goal is to see if the drug is safe and effective at contr…

This early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…

This study is testing whether the drug risankizumab can safely keep ulcerative colitis under control for a year or more in people who initially responded to it. It involves 1,242 participants who will receive either the drug or a placebo to compare results. The main goals are to …

This study is testing a two-part treatment for ovarian cancer that has come back after initial chemotherapy. It combines a standard chemotherapy drug with a newer, targeted drug designed to attack cancer cells with a specific marker. After the combination phase, patients continue…

This study is observing the long-term safety and effectiveness of the OZURDEX eye implant in patients with diabetic macular edema (DME) in China. The implant slowly releases medication to reduce swelling in the retina. About 110 patients who are already prescribed OZURDEX by thei…

This study is testing an investigational drug called lutikizumab for adults with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. It aims to see if lutikizumab is safe, effective, and works as well as or better than an existing treatment (adalimumab). …

This study is observing how well the drug venetoclax works for people with acute myeloid leukemia (AML) during their normal medical care in Israel. It will follow 100 patients to see how long they live, if their cancer goes into remission, and how their quality of life changes. T…

This study is testing whether adding the medication elagolix to standard birth control pills works better for controlling moderate to severe pain from endometriosis. About 800 women with surgically confirmed endometriosis will participate. For the first 3 months, participants wil…

This study compares two already-approved medicines for moderate plaque psoriasis. It tests if an injection given every 12 weeks (risankizumab) works better than a daily pill (deucravacitinib) at clearing skin. About 336 adults who have not tried biologic treatments will participa…

This study aims to understand the long-term safety and effectiveness of the drug upadacitinib for adults with ulcerative colitis. It is for people who have already participated in related earlier studies, either because their condition did not improve enough or they lost their re…

This large, late-stage study is testing if a daily pill called upadacitinib can help repigment skin in people with non-segmental vitiligo, an autoimmune condition that causes white patches. About 614 participants will be randomly assigned to receive either the active drug or a pl…

This study is testing whether adding an oral medication called upadacitinib to standard steroid creams is safe and works better for controlling moderate to severe eczema in young children in Japan. About 99 children aged 2 to 11 will take either the real pill or a placebo (sugar …

This study follows patients with diabetic macular edema (DME), a vision-threatening eye swelling, who didn't respond well to standard anti-VEGF injections. Doctors will observe how these patients do when switched to a slow-release steroid implant (DEX-I) in their regular clinical…

This program provided early access to an investigational drug called fosigotifator for people with vanishing white matter disease and Cree leukoencephalopathy—two rare, serious brain disorders. It was designed to make the treatment available to eligible patients before it receive…

This study aims to understand how well the approved drug venetoclax works in real-world settings for adults with acute myeloid leukemia (AML) who are too old or frail for standard intensive chemotherapy. It will follow about 200 patients across Canada for three years, collecting …

This is a very early-stage study to test the safety and find the right dose of a new oral drug called ABBV-453 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to at least two prior treatments. Particip…

This study allows patients already receiving venetoclax in other trials to continue treatment if they are benefiting and tolerating it well. The main goal is to collect long-term safety information by tracking any side effects. It includes about 165 patients with various blood ca…

This is the first study in people to test the safety and early effectiveness of an investigational drug called ABBV-400 for adults with advanced solid tumors that have stopped responding to standard treatments. The study will find the best dose of ABBV-400 given alone and will al…

This is the first human study of an experimental drug called ABBV-706 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug, while also checking for early signs tha…

This study is for adults with myelofibrosis, a rare blood cancer, that has come back or not improved after prior treatment. It compares a new two-drug combination (navitoclax + ruxolitinib) against the current best available treatments to see which is better at reducing spleen si…

This study is testing the safety and best dose of an experimental drug called etentamig when given with other standard cancer drugs to adults with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to see how well patients tolerate the…

This study is testing whether an injectable medication called risankizumab can help control symptoms and reduce gut inflammation in adults with moderate to severe Crohn's disease. Participants will receive either the active drug or a placebo injection for up to 24 weeks, followed…

This is a first-in-human study to find the safest and most effective doses of two new immunotherapy drugs, ABBV-927 and ABBV-181, for people with advanced solid tumors. The main goal is to see how the body handles the drugs and what side effects occur. Researchers will also gathe…

This study is observing how well the already-approved oral medication upadacitinib (RINVOQ) works for controlling moderate-to-severe eczema over two years in real-world medical settings. It involves about 770 adolescents and adults in Germany who are already prescribed this medic…

This study is testing a potential one-time gene therapy called RGX-314 for diabetic retinopathy, a leading cause of vision loss. The goal is to see if a single injection can slow or reverse the eye damage caused by diabetes, reducing the need for the frequent eye injections that …

This study is testing a new drug called ABBV-400, given with standard chemotherapy drugs, for adults with advanced colorectal cancer that has spread and cannot be removed by surgery. The goal is to find the safest and most effective dose and see if this combination can help contr…

This study is testing if a daily pill called upadacitinib, when used with a standard steroid cream, is safe and effective for controlling moderate to severe eczema (atopic dermatitis). It involves over 1,500 teens and adults whose eczema is not well-controlled with creams alone. …

This program provided early access to an investigational drug called ABBV-787 for people with acute myeloid leukemia before it received full regulatory approval. It was designed for eligible patients who had no other suitable treatment options and could not join ongoing clinical …

This study is testing a new injectable drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 participants will receive either the drug or a placebo via injection every other week for 16 weeks, followed by the drug for another 32 weeks. Th…

This study is testing the safety and effectiveness of the drug upadacitinib for children with moderate-to-severe ulcerative colitis who haven't responded well to other standard treatments. About 110 children worldwide will take the medication daily and be closely monitored for ov…

This study is testing an experimental antibody called TNB-383B in people with advanced multiple myeloma that has returned or stopped responding to at least three previous treatments. Researchers are giving different doses to find the safest and most effective amount, while closel…

This study aims to see how satisfied patients are with two already-approved migraine medications, ubrogepant and atogepant, when used in everyday life. It will follow about 200 adults in Israel who are prescribed one of these drugs by their doctor for 90 days. The main goal is to…

This study is testing how safe and effective JUVÉDERM facial filler products are for adults who have lost a significant amount of weight through medical programs. It involves 75 participants who want to improve lost facial volume or skin quality. Researchers will measure how sati…

This study aims to collect safety information and patient satisfaction data for the CoolSculpting Elite system, a non-surgical fat reduction treatment. Researchers are gathering information from 102 people who received treatments on their chin, inner thighs, or back/bra areas. Th…

This study aims to find out how satisfied people are with their overall face and neck appearance after receiving a combination of common cosmetic treatments. It will enroll 130 diverse participants who will receive treatments like Botox, Juvéderm fillers, Kybella, CoolSculpting, …

This early-stage study aims to check the safety and basic effects of a new drug called ABBV-701 in healthy people. It will involve about 100 healthy adults from Western and Asian backgrounds. Researchers will give participants different single doses to see how the drug moves thro…

This early-stage study aims to understand how a common antifungal drug (itraconazole) affects how the body processes an experimental medication called ABBV-932. It involves about 20 healthy adult volunteers who will take both drugs. The main goal is to measure drug levels in the …

This is an early safety study testing an experimental drug called ABBV-8736 in healthy adults. The main goal is to see how safe the drug is, how the body processes it, and if it causes an immune response. Researchers will give different doses to small groups of healthy volunteers…

This is an early, small study to understand how the body absorbs and processes a new tablet drug called ABBV-722. It involves 11 healthy volunteers and tests whether taking the drug with or without food changes how much of it gets into the bloodstream. The main goal is to gather …

This study aimed to track hair changes in women taking Oriahnn for uterine fibroids. Researchers planned to follow 1,600 women for two years to understand how often hair loss occurs, when it starts, and if it improves. The study was withdrawn before any participants were enrolled…

This is an early, small study to understand how the body absorbs different pill versions of an experimental drug called ABBV-932. It will test how much of the drug gets into the bloodstream and if taking it with food changes that. The study involves 9 healthy adult volunteers to …

This is a very early, first-in-human study to check the safety of a new drug called ABBV-142 and see how it moves through the body. It involves 73 healthy adult volunteers who will receive a single dose. The main goal is to find a safe dose range and understand the drug's basic b…